An investigation for investors in shares of C R Bard Inc (NYSE:BCR) was announced over potential breaches of fiduciary duties by certain directors at C R Bard Inc. The investigation concerns whether C.R. Bard potentially knew about fatal flaws associated with the G2 series filters they manufactured.
Investors who purchased shares of C R Bard Inc (NYSE:BCR) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain C R Bard officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
According to the investigation the modified version of the blood-clot filter was meant to replace the original Recovery Filter, but was similarly mired by device flaws. According to the investigation the Recovery filter was found to have higher rates of relative risk of filter facture, movement, and death according to a confidential study commissioned by C.R. Bard, that the G2 filter had similar problems and now, hundreds of complications and at least twelve deaths have been linked to the device, and that instead of recalling the G2 filter, C.R. Bard kept it on the market for five subsequent years.
C.R. Bard, Inc. reported that its annual Total Revenue rose from over $3.04 billion in 2013 to over $3.32 billion in 2014 while its respective Net Income decreased from $689.80 million to $294.50 million. Shares of C.R. Bard, Inc. (NYSE:BCR) grew from $85.68 per share in early 2012 to as high as $199.53 per share in August 2015.
On January 26, 2016, NYSE:BCR shares closed at $183.16 per share.
Those who purchased shares of C R Bard Inc (NYSE:BCR), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego